Regenxbio Inc
RGNX11.210USD
+0.040+0.36%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
567.44MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Regenxbio Inc Unternehmen
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Inc Informationen
BörsenkürzelRGNX
Name des UnternehmensRegenxbio Inc
IPO-datumSep 17, 2015
CEOMr. Curran M. Simpson
Anzahl der mitarbeiter353
WertpapierartOrdinary Share
GeschäftsjahresendeSep 17
Addresse9804 Medical Center Drive
StadtROCKVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl20850
Telefon12405528181
Websitehttps://regenxbio.com/
BörsenkürzelRGNX
IPO-datumSep 17, 2015
CEOMr. Curran M. Simpson
Führungskräfte von Regenxbio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.59K
-1.31%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.11K
-48.81%
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
53.97K
-8.33%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.59K
-1.31%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Nov 8
Aktualisiert: Sat, Nov 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
9.43%
BlackRock Institutional Trust Company, N.A.
8.43%
The Vanguard Group, Inc.
6.59%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
Andere
64.66%
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
9.43%
BlackRock Institutional Trust Company, N.A.
8.43%
The Vanguard Group, Inc.
6.59%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
Andere
64.66%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
33.94%
Investment Advisor
31.21%
Hedge Fund
12.74%
Individual Investor
7.62%
Research Firm
6.92%
Pension Fund
0.28%
Bank and Trust
0.26%
Family Office
0.26%
Private Equity
0.06%
Andere
6.73%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
2023Q2
439
43.86M
100.57%
-5.31M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Redmile Group, LLC
4.78M
9.45%
-19.06K
-0.40%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.27M
8.45%
+348.80K
+8.90%
Jun 30, 2025
The Vanguard Group, Inc.
3.42M
6.77%
-51.80K
-1.49%
Jun 30, 2025
Fox (Allan Mark)
2.90M
5.74%
+7.77K
+0.27%
May 30, 2025
JP Morgan Asset Management
2.99M
5.91%
+38.82K
+1.32%
Jun 30, 2025
State Street Investment Management (US)
1.84M
3.65%
+777.55K
+72.93%
Jun 30, 2025
BlackRock Financial Management, Inc.
1.73M
3.43%
+637.97K
+58.36%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.61M
3.18%
+962.62K
+149.64%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.13M
2.23%
+21.57K
+1.95%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.12M
2.22%
-24.96K
-2.17%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
WisdomTree BioRevolution Fund
1.92%
iShares Neuroscience and Healthcare ETF
0.79%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Global X Genomics & Biotechnology ETF
0.51%
JPMorgan Fundamental Data Science Small Core ETF
0.32%
ALPS Medical Breakthroughs ETF
0.29%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
iShares Health Innovation Active ETF
0.09%
Fidelity Enhanced Small Cap ETF
0.08%
Mehr Anzeigen
WisdomTree BioRevolution Fund
Anteil1.92%
iShares Neuroscience and Healthcare ETF
Anteil0.79%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.68%
Global X Genomics & Biotechnology ETF
Anteil0.51%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.32%
ALPS Medical Breakthroughs ETF
Anteil0.29%
SPDR S&P Biotech ETF
Anteil0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.09%
iShares Health Innovation Active ETF
Anteil0.09%
Fidelity Enhanced Small Cap ETF
Anteil0.08%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
